SGAM
KITE

Smith Group Asset Management’s Kite Pharma, Inc. KITE Stock Holding History

Smith Group Asset Management’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-9,860
Closed -$1.02M – 490
2017
Q2 		$1.02M Buy
9,860
+2,920
+42% +$238K 0.03% 166
2017
Q1 		$545K Sell
6,940
-194
-3% -$12K 0.02% 181
2016
Q4 		$316K Buy
7,134
+98
+1% +$4.81K 0.01% 219
2016
Q3 		$391K Buy
7,036
+86
+1% +$4.79K 0.01% 198
2016
Q2 		$348K Sell
6,950
-100
-1% -$4.91K 0.01% 208
2016
Q1 		$324K Sell
7,050
-80
-1% -$3.88K 0.01% 176
2015
Q4 		$439K Buy
+7,130
New +$502K 0.01% 207

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Smith Group Asset Management's KITE Position: Q3 2017 in Review

Smith Group Asset Management sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 9,860 shares — an estimated $1.02M sold.

Smith Group Asset Management first reported a position in KITE in Q4 2015 and held it in 7 quarters. The position peaked at $1.02M in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Smith Group Asset Management reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Smith Group Asset Management sold 9,860 Kite Pharma, Inc. shares in Q3 2017, an estimated $1.02M.
  • Smith Group Asset Management first reported a position in Kite Pharma, Inc. in Q4 2015 and held it in 7 quarters.
  • Smith Group Asset Management's Kite Pharma, Inc. position peaked at $1.02M in Q2 2017.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Smith Group Asset Management's 13F filing for Q3 2017, filed 2 Nov 2017.